Oncosem Signs TRY 273 Million Contract with Çam and Sakura Hospital

Oncosem has signed a significant contract with Başakşehir Çam and Sakura City Hospital for the provision of chemotherapy drug preparation services. According to the company's statement, the contract covers a five-year period with a total value of TRY 272.999 million. This agreement is considered an important step in line with Oncosem's strategy to expand its service portfolio in the healthcare sector. The preparation of chemotherapy drugs is a critical process for hospitals, and expertise and capacity in this area could provide a predictable contribution to the company's revenues. The duration and size of the contract are among the factors expected to have a positive impact on Oncosem's future financial performance. A fixed revenue stream over five years could strengthen the company's cash flow planning and enhance operational stability. Investors should consider that such long-term agreements indicate the company's growth potential. However, operational risks and cost variations that may arise during the implementation of the contract should also be taken into account. This is not investment advice.